Error loading player: No playable sources found
2215
Clinical Advances in Steatotis Liver Disease and MASH
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AGA Newer and novel tools in understanding and management of patients with MASLD
Presentations:
| LEAN VETERANS WITH MASLD HAVE SIGNIFICANTLY GREATER RISK OF CARDIOVASCULAR EVENTS AND ALL-CAUSE MORTALITY COMPARED TO OVERWEIGHT/OBESE VETERANS WITH MASLD |
| PARENTAL OBESITY AT PREGNANCY WITH RISK OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE IN YOUNG ADULT OFFSPRING |
| (WITHDRAWN) ALTERATION OF GUT MICROBIOME AND METABOLITES IN WILSON’S DISEASE |
| IMPACT OF BARIATRIC SURGERY ON HOSPITAL OUTCOMES IN PATIENTS ADMITTED WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A 2020 RETROSPECTIVE ANALYSIS IN THE UNITED STATES |
| STATIN THERAPY AND IMPROVED WAITLIST OUTCOMES IN LIVER TANS PANT CANDIDATES WITH METABOLIC DYSFUNCTION ASSOCIATED STEATOHEPATITIS (MASH) CIRRHOSIS |
| THE CONTINUED ALARMING RISE IN RATES OF ALCOHOL ASSOCIATED HEPATITIS AMONG U.S. VETERANS PERSISTS BEYOND THE COVID-19 PANDEMIC |
Moderators
Beth Israel Deaconess Medical Center
Virginia Commonwealth Univ.
Speakers
Tracks
Related Products
Portal Hypertension: Advances in Management of Disease
SOCIETY: AGA Updates and newer management strategies for portal hypertension in patients with liver disease…
Microbiome & Microbial Therapy (MMT) Section Distinguished Abstract Plenary
SOCIETY: AGA This session will feature a selection of the best abstracts submitted to the micobiome and microbial therapy section which encompass DGBI, IBD, cancer and liver disease…
AASLD Presidential Plenary
ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
